Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904770 | 0.86 | CKS1B (0.45) | PIM1PIM3PIM2SYKRET | |
| SCHEMBL15440351 | 0.83 | CKS1B (0.41) | ALOX5APFEN1RETCKS1BSKP1 | |
| SCHEMBL9904737 | 0.82 | WNT1 (0.39) | BTKALOX5APFEN1RETBRD4 | |
| SCHEMBL9904148 | 0.82 | PIM1 (0.48) | PIM1PIM3PIM2 | |
| SCHEMBL9904147 | 0.82 | PIM1 (0.48) | PIM1PIM3PIM2 | |
| SCHEMBL9904145 | 0.82 | PIM1 (0.48) | PIM1PIM3PIM2 | |
| SCHEMBL9904327 | 0.81 | CKS1B (0.44) | SYKJAK3BTKRETCKS1B | |
| SCHEMBL15440453 | 0.80 | AURKA (0.46) | PIM1PIM3PIM2AURKAPDPK1 | |
| SCHEMBL9904300 | 0.80 | BTK (0.41) | PIM1PIM2SYKBTKEGFR | |
| SCHEMBL9904303 | 0.80 | BTK (0.41) | PIM1PIM2SYKBTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.